<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376896</url>
  </required_header>
  <id_info>
    <org_study_id>CRI103147</org_study_id>
    <nct_id>NCT00376896</nct_id>
  </id_info>
  <brief_title>Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers</brief_title>
  <official_title>A Phase IIa Experimental Medicine Study Assessing Alterations in Regional Cerebral Blood Flow by Functional Magnetic Resonance Imaging (fMRI) in Female IBS Patients and Healthy Controls Following Single Doses of GW876008, a Corticotrophin Releasing Factor 1 Receptor Antagonist (CRF1-RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is a three-period crossover study to compare GW876008 and placebo to see if GW876008
      will normalise blood flow responses after different emotional stimuli.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Signal reductions in the amygdala during viewing of emotional faces and during abdominal pain threat as measured by the fMRI.</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaires to assess IBS symptoms and anxiety</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Irritable Colon</condition>
  <condition>Irritable Bowel Syndrome (IBS)</condition>
  <arm_group>
    <arm_group_label>GW876008 20mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GW876008 20mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GW876008 200mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GW876008 200mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW876008 200mcg</intervention_name>
    <description>GW876008</description>
    <arm_group_label>GW876008 200mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW876008 20mcg</intervention_name>
    <description>GW876008 20mcg</description>
    <arm_group_label>GW876008 20mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject should not have been taking and medication for the treatment of IBS for 1
             month prior to the study

          -  Negative serum pregnancy tests (serum a-HCG negative) at Screening (Visit 1), and
             negative urine pregnancy tests at Visits 1, 2, 3 prior to study medication dose.

          -  Non-tobacco user (abstinence from tobacco use for at least 1 month before the start of
             the study).

          -  Normal electrocardiogram (subjects must have no clinically significant abnormalities
             on a 12-lead ECG at screen).

        Exclusion Criteria:

          -  Subjects who are pregnant or nursing.

          -  Current evidence, or history of (at any time in the past) of a biochemical or
             structural abnormality of the digestive tract. including (but not limited to):
             inflammatory bowel disease (Crohn's disease or ulcerative colitis); functional
             dyspepsia; lactose intolerance, not on a stable diet; Celiac Disease

          -  Subjects who are taking NSAIDs on a regular basis or within 48 hours of a study day.

          -  The subject has a positive pre-study urine drug/alcohol screen.

          -  A positive pre-study HIV 1 / 2, Hepatitis B surface antigen or positive Hepatitis C
             antibody result within 3 months of the start of the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, Dr</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2006</study_first_submitted>
  <study_first_submitted_qc>September 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2006</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBS fMRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corticotropin-Releasing Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

